Proteins > Proteasome subunit beta type-2
Page last updated: 2024-08-07 18:37:00
Proteasome subunit beta type-2
A proteasome subunit beta type-2 that is encoded in the genome of human. [PRO:DNx]
Synonyms
Macropain subunit C7-I;
Multicatalytic endopeptidase complex subunit C7-I;
Proteasome component C7-I
Research
Bioassay Publications (45)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (11.11) | 29.6817 |
2010's | 30 (66.67) | 24.3611 |
2020's | 10 (22.22) | 2.80 |
Compounds (26)
Drugs with Inhibition Measurements
Drugs with Activation Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
am 404 | Homo sapiens (human) | EC50 | 28.0000 | 1 | 1 |
Drugs with Other Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
chlorpromazine | Homo sapiens (human) | EC200 | 45.1250 | 4 | 4 |
bortezomib | Homo sapiens (human) | Ki50 | 1.0750 | 2 | 2 |
pr-957 | Homo sapiens (human) | Ki50 | 1.2250 | 2 | 2 |
Discovery of a Novel Oral Proteasome Inhibitor to Block NLRP3 Inflammasome Activation with Anti-inflammation Activity.Journal of medicinal chemistry, , 09-22, Volume: 65, Issue:18, 2022
Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment.European journal of medicinal chemistry, , Apr-05, Volume: 233, 2022
Structure-Based Design of Selective LONP1 Inhibitors for Probing Journal of medicinal chemistry, , 04-22, Volume: 64, Issue:8, 2021
Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.European journal of medicinal chemistry, , Feb-15, Volume: 164, 2019
Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.European journal of medicinal chemistry, , Nov-15, Volume: 182, 2019
Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.European journal of medicinal chemistry, , Feb-15, Volume: 164, 2019
Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studBioorganic & medicinal chemistry, , 08-07, Volume: 26, Issue:14, 2018
Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.Journal of medicinal chemistry, , 11-21, Volume: 61, Issue:22, 2018
Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death.European journal of medicinal chemistry, , Feb-25, Volume: 146, 2018
Immunoproteasome inhibition and bioactivity of thiasyrbactins.Bioorganic & medicinal chemistry, , 01-15, Volume: 26, Issue:2, 2018
Urea-containing peptide boronic acids as potent proteasome inhibitors.European journal of medicinal chemistry, , Jan-05, Volume: 125, 2017
Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors.Bioorganic & medicinal chemistry, , 08-01, Volume: 25, Issue:15, 2017
Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.Bioorganic & medicinal chemistry, , Jun-01, Volume: 22, Issue:11, 2014
Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.Journal of medicinal chemistry, , Mar-27, Volume: 57, Issue:6, 2014
Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of Belactosin A: synthesis, biological activity, and mode of action.Journal of medicinal chemistry, , May-09, Volume: 56, Issue:9, 2013
Molecular mechanisms of acquired proteasome inhibitor resistance.Journal of medicinal chemistry, , Dec-13, Volume: 55, Issue:23, 2012
Development of isoquinolinone derivatives as immunoproteasome inhibitors.Bioorganic & medicinal chemistry letters, , 01-01, Volume: 55, 2022
Synthesis and Biological Activity of Peptide α-Ketoamide Derivatives as Proteasome Inhibitors.ACS medicinal chemistry letters, , Jul-11, Volume: 10, Issue:7, 2019
Identification of neomacrophorins isolated from Trichoderma sp. 1212-03 as proteasome inhibitors.Bioorganic & medicinal chemistry, , 12-15, Volume: 27, Issue:24, 2019
Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors.Bioorganic & medicinal chemistry letters, , 02-01, Volume: 28, Issue:3, 2018
Development of novel proteasome inhibitors based on phthalazinone scaffold.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 26, Issue:12, 2016
Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening.European journal of medicinal chemistry, , Oct-04, Volume: 121, 2016
A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor.European journal of medicinal chemistry, , Volume: 71, 2014
Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.Journal of medicinal chemistry, , May-18, Volume: 49, Issue:10, 2006
Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 15, Issue:7, 2005
Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.Journal of medicinal chemistry, , May-18, Volume: 49, Issue:10, 2006
P3 and P4 position analysis of vinyl ester pseudopeptide proteasome inhibitors.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 16, Issue:12, 2006
Natural products from mangrove sediments-derived microbes: Structural diversity, bioactivities, biosynthesis, and total synthesis.European journal of medicinal chemistry, , Feb-15, Volume: 230, 2022
Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.European journal of medicinal chemistry, , Nov-15, Volume: 182, 2019
Molecular mechanisms of acquired proteasome inhibitor resistance.Journal of medicinal chemistry, , Dec-13, Volume: 55, Issue:23, 2012
Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease.Journal of medicinal chemistry, , 08-12, Volume: 64, Issue:15, 2021
Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.European journal of medicinal chemistry, , Feb-15, Volume: 164, 2019
Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.European journal of medicinal chemistry, , Nov-15, Volume: 182, 2019
Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.European journal of medicinal chemistry, , Jan-01, Volume: 161, 2019
Reviewing Hit Discovery Literature for Difficult Targets: Glutathione Transferase Omega-1 as an Example.Journal of medicinal chemistry, , 09-13, Volume: 61, Issue:17, 2018
Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.European journal of medicinal chemistry, , Sep-05, Volume: 157, 2018
Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.Bioorganic & medicinal chemistry, , Jun-01, Volume: 22, Issue:11, 2014
Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morphoJournal of medicinal chemistry, , 12-27, Volume: 61, Issue:24, 2018
Structure-based design of human immuno- and constitutive proteasomes inhibitors.European journal of medicinal chemistry, , Feb-10, Volume: 145, 2018
Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.ACS medicinal chemistry letters, , Apr-13, Volume: 8, Issue:4, 2017
Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.Journal of medicinal chemistry, , Mar-27, Volume: 57, Issue:6, 2014
Development of a new class of proteasome inhibitors with an epoxyketone warhead: Rational hybridization of non-peptidic belactosin derivatives and peptide epoxyketones.Bioorganic & medicinal chemistry, , Jun-15, Volume: 22, Issue:12, 2014
[no title available]Journal of medicinal chemistry, , 01-09, Volume: 63, Issue:1, 2020
Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.European journal of medicinal chemistry, , Nov-15, Volume: 182, 2019
Molecular mechanisms of acquired proteasome inhibitor resistance.Journal of medicinal chemistry, , Dec-13, Volume: 55, Issue:23, 2012
Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors.Bioorganic & medicinal chemistry letters, , 11-01, Volume: 30, Issue:21, 2020
Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.European journal of medicinal chemistry, , Jan-01, Volume: 161, 2019
Enables
This protein enables 1 target(s):
Target | Category | Definition |
protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
Located In
This protein is located in 5 target(s):
Target | Category | Definition |
nucleus | cellular component | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. [GOC:go_curators] |
nucleoplasm | cellular component | That part of the nuclear content other than the chromosomes or the nucleolus. [GOC:ma, ISBN:0124325653] |
cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
membrane | cellular component | A lipid bilayer along with all the proteins and protein complexes embedded in it and attached to it. [GOC:dos, GOC:mah, ISBN:0815316194] |
extracellular exosome | cellular component | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. [GOC:BHF, GOC:mah, GOC:vesicles, PMID:15908444, PMID:17641064, PMID:19442504, PMID:19498381, PMID:22418571, PMID:24009894] |
Active In
This protein is active in 3 target(s):
Target | Category | Definition |
nucleus | cellular component | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. [GOC:go_curators] |
cytoplasm | cellular component | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. [ISBN:0198547684] |
cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
Part Of
This protein is part of 3 target(s):
Target | Category | Definition |
proteasome complex | cellular component | A large multisubunit complex which catalyzes protein degradation, found in eukaryotes, archaea and some bacteria. In eukaryotes, this complex consists of the barrel shaped proteasome core complex and one or two associated proteins or complexes that act in regulating entry into or exit from the core. [GOC:rb, Wikipedia:Proteasome] |
proteasome core complex | cellular component | A multisubunit barrel shaped endoprotease complex, which is the core of the proteasome complex. [GOC:rb, PMID:10806206] |
proteasome core complex, beta-subunit complex | cellular component | The proteasome core subcomplex that constitutes the two inner rings of the proteasome core complex. An example of this component is found in Mus musculus. [GOC:jl, GOC:mtg_sensu, GOC:rb, PMID:10854779] |
Involved In
This protein is involved in 3 target(s):
Target | Category | Definition |
response to organonitrogen compound | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organonitrogen stimulus. An organonitrogen compound is formally a compound containing at least one carbon-nitrogen bond. [PMID:9869419] |
response to organic cyclic compound | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organic cyclic compound stimulus. [GOC:ef] |
proteasome-mediated ubiquitin-dependent protein catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome. [GOC:go_curators] |